Please provide your email address to receive an email when new articles are posted on . Phase 1 pharmacokinetics results showed comparability between SB17 and ustekinumab. Phase 3 results of SB17 will ...
On Tuesday, May 23, 2023, Janssen and Amgen settled their case regarding Amgen’s proposed biosimilar to Stelara in Delaware district court.[1] Stelara, also known as ustekinumab, is an ...
(Reuters) - Johnson & Johnson's legal settlement with Amgen Inc to delay a biosimilar version of its blockbuster psoriasis treatment Stelara until January 2025 could make the drug a larger contributor ...
May 23 (Reuters) - Johnson & Johnson (JNJ.N), opens new tab has settled its lawsuit over Amgen Inc's (AMGN.O), opens new tab proposed biosimilar version of J&J's top-selling treatment Stelara for ...
SEOUL, South Korea--(BUSINESS WIRE)--Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has ...
Partners STADA and Alvotech today announced that the European Commission issued a marketing authorization for Uzpruvo® (AVT04), a biosimilar candidate to Stelara® (ustekinumab). The centralized ...
Evernorth Health Services, a subsidiary of Cigna, plans to have a Stelara biosimilar available for $0 out-of-pocket cost for eligible patients of its specialty pharmacy, Accredo, beginning in early ...
RALEIGH, N.C., Aug. 18, 2025 /PRNewswire/ -- Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology ...
(RTTNews) - Bio-Thera Solutions and Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (RDY), announced that they have reached commercialization and license ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback